Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years or older.~* Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ≥1 year before the screening visit .~* Eczema Area and Severity Index (EASI) score ≥16 at the screening and the baseline visit.~* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the screening and the baseline visit.~* ≥10% body surface area (BSA) of AD involvement at the screening and the baseline visit.~Exclusion Criteria:~* Treatment with any of the following agents within 4 weeks prior to the baseline visit:~* Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)~* Phototherapy and photochemotherapy (PUVA) for AD.~* Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 week prior to the baseline visit.~* Treatment with:~* An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, prior to the baseline visit.~* Dupilumab within 3 months prior to baseline visit.~* Cell-depleting biologics, including rituximab, within 6 months prior to the baseline visit.~* Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit (whichever is longer).~* Use of prescription moisturizers within 7 days of the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W) (Type: EXPERIMENTAL): 125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo.
- 250 mg Lebrikizumab - Q4W (Type: EXPERIMENTAL): 250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo.
- 250 mg Lebrikizumab - Every 2 Weeks (Q2W) (Type: EXPERIMENTAL): 250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab).
- Group 4 - Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete